ANI Pharmaceuticals

Historical price data

ANI Pharmaceuticals has evolved from a generic drug manufacturer into a diversified biopharmaceutical company with a three-pillar strategy: Rare Disease, Generics, and Established Brands. A key achievement was the transformative acquisition of Novitium Pharma, which significantly expanded its R&D capabilities, manufacturing footprint, and specialty portfolio. Under CEO Nikhil Lalwani, the company is focused on delivering sustainable growth by commercializing novel therapies for underserved patient populations while maintaining the stable cash flows of its legacy businesses.

ANI's core platform is an integrated development and manufacturing engine specializing in complex formulations, supported by vertically integrated, FDA-inspected U.S. facilities and a deep expertise in regulatory strategy for generics and specialty products.

ANI competes in two arenas: against large biopharma and niche biotechs in rare diseases, and against large generic manufacturers in complex generics. Its hybrid model is a key differentiator, allowing it to use generics cash flow to fund specialty growth while competing on formulation expertise and U.S.-based manufacturing.